Expanding Non-Injectable Insulin Market Fueled by Escalating Obesity and Diabetes Epidemics: An Emerging Driver Transforming The Non-injectable Insulin Market Landscape

The Non-injectable Insulin Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Projected Growth of the Non-injectable Insulin Market?
The market size for non-injectable insulin has experienced brisk expansion in the past few years. Projected growth sees it increasing from $1.92 billion in 2024 to $2.16 billion in 2025, boasting a compound annual growth rate (CAGR) of 12.1%. Factors contributing to this upward trend during the historic period include enhancements to patient compliance, resolutions to needle phobia, upgrades to the quality of life, simplified administration, and effective control over blood glucose levels.

The market size for non-injectable insulin is predicted to experience substantial expansion in the coming years. It is anticipated to reach $3.17 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 10.1%. Factors driving growth during this forecast period include sustained efforts to ensure patient adherence, ongoing solutions for needle phobia, further enhancements in the quality of life, never-ending improvements in safety, and decreasing risk of infection and injury. Key trends predicted for this period involve advancements in technology, progression of tech-solutions, incorporation of digital health, nanotech use, and combined therapies.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13888

What Are the Different Non-injectable Insulin Market Segments?
The non-injectable insulin market covered in this report is segmented -

1) By Type: Synthetic Insulin, Semi Synthetic Insulin
2) By Product: Pills, Sprays, Other Products
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Drug Stores

Subsegments:
1) By Synthetic Insulin: Rapid-Acting Synthetic Insulin, Short-Acting Synthetic Insulin, Intermediate-Acting Synthetic Insulin, Long-Acting Synthetic Insulin
2) By Semi-Synthetic Insulin: Modified Insulin Analogs, Combination Insulins, Biosimilar Insulins, Insulin With Extended Release Formulations

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13888&type=smp

What Are the Primary Drivers Shaping the Non-injectable Insulin Market?
The surge in obesity and diabetes-related problems is anticipated to stimulate the expansion of the non-injectable insulin market. Obesity, typified by excessive body fat accumulation due to an energy imbalance between consumption and expenditure, and diabetes mellitus, commonly known as diabetes, characterized by extended periods of elevated blood sugar - are both administered with non-injectable insulin. This form of treatment addresses concerns associated with insulin therapy, offers potential weight management advantages, and introduces more convenient treatment modalities. For instance, the World Heart Federation, a non-governmental organization based in Switzerland, forecasted in 2022 that global obesity rates will skyrocket. The number of overweight and obese individuals, including both children and adults, stood at an estimated 2.3 billion in 2021 and is projected to rise to 2.7 billion by 2025. Additionally, in April 2023, a report by the British Diabetic Association, a diabetes charity based in the UK, stated that 4.3 million people in the UK have diabetes, with over 2.4 million at risk of developing type 2 diabetes. The enrolment numbers for 2021-22 showed a sharp rise of 148,951 from the previous year. Consequently, the escalating issues surrounding obesity and diabetes are propelling the non-injectable insulin market's growth.

Which Companies Are Leading in the Non-injectable Insulin Market?
Major companies operating in the non-injectable insulin market report are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A, Bristol-Myers Squibb Company, AstraZeneca, Abbott Laboratories, GlaxoSmithKline, Takeda Pharmaceutical, Eli Lilly and Company, Boehringer Ingelheim, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Ipsen S.A., Cadila Healthcare Limited, Dr. Reddy's Laboratories Limited, Cipla Limited, Lupin Pharmaceuticals, Glenmark Pharmaceuticals, Torrent Pharmaceuticals, Biocon Limited, Wockhardt Limited

What Are the Major Trends Shaping the Non-injectable Insulin Market?
Leading firms in the non-injectable insulin market are prioritizing revolutionary advancements in drug dispatch mechanisms, such as non-needle oral insulin sprays, to enhance the quality of life for individuals managing diabetes through regular insulin injections. The oral insulin spray is a hassle-free and non-invasive method of maintaining blood glucose levels as it allows for administering the doses directly into the mouth. For instance, in November 2023, Ozulin, a non-injectable insulin spray, was launched by the Indian company NiedlFree Technologies. The device aims to provide an easier method for diabetics, especially those facing difficulties with traditional insulin injection methods. If endorsed, Ozulin can significantly transform the diabetes care landscape by providing a more user-friendly and non-painful alternative to insulin injections.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/non-injectable-insulin-global-market-report

What Are the Top Revenue-Generating Geographies in the Non-injectable Insulin Market?
North America was the largest region in the non-injectable insulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-injectable insulin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Non-injectable Insulin Market?
2. What is the CAGR expected in the Non-injectable Insulin Market?
3. What Are the Key Innovations Transforming the Non-injectable Insulin Industry?
4. Which Region Is Leading the Non-injectable Insulin Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.